Mats Lek

All filings by Mats Lek on record concern Swedish Orphan Biovitrum AB (publ). We count 5 filings; the first trade dates from 9 August 2023 and the latest from 12 June 2026.

Market trades split into 2 purchases (€1,804) and 1 sale (€82). The net balance comes to €1,722 on the buying side. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Outside the open market, there are 2 share grants.

Most recently, on 15 June 2026, the filings show a share grant in Swedish Orphan Biovitrum AB (publ). The last purchase on record was published on 19 September 2023, which is 1,147 days ago. Typically, a trade is published a median of 3 days after it takes place. For comparison, MAR article 19 gives managers three business days to notify a trade. This summary is built from Finansinspektionen disclosures alone and does not predict where the share price will go.